Physician profile
Daniel W Broadbent
NPI 1699901231
$6,985.78
in general payments reported to CMS, 2019-2025
58 companies · $1,377 in 2025
The $1,377 reported for 2025 was more than what 91% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $573 · 2020: $516 · 2021: $1,015 · 2022: $1,124 · 2023: $1,122 · 2024: $1,258 · 2025: $1,377.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,733 · Education: $25.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,732.74 |
| Education | $25.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,447.19 | 2020-2025 | Vraylar, Ubrelvy, Qulipta |
| Astrazeneca Pharmaceuticals LP | $791.97 | 2020-2025 | Breztri, Farxiga, Airsupra |
| Novo Nordisk INC | $746.55 | 2019-2025 | Ozempic, Wegovy, Rybelsus |
| Supernus Pharmaceuticals, INC. | $435.61 | 2022-2025 | Qelbree, Qelbree |
| Lilly USA, LLC | $349.67 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Amgen INC. | $244.93 | 2019-2022 | |
| Glaxosmithkline, LLC. | $240.45 | 2019-2025 | Shingrix, Trelegy Ellipta, Arexvy |
| Pfizer INC. | $216.79 | 2019-2025 | |
| Viiv Healthcare Company | $179.44 | 2024-2025 | Apretude |
| Takeda Pharmaceuticals U.S.A., INC. | $170.92 | 2019-2024 | Trintellix |
| Idorsia Pharmaceuticals US INC | $156.58 | 2022-2025 | Quviviq, Quviviq |
| Abbott Laboratories | $138.60 | 2021-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Janssen Pharmaceuticals, INC | $132.48 | 2020-2025 | Spravato |
| Merck Sharp & Dohme LLC | $125.83 | 2019-2025 | Verquvo, Belsomra, Steglatro |
| Biohaven Pharmaceutical Holding Company LTD. | $104.05 | 2022 |
Show all 58 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Broadbent listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.